Skip to main content

Advertisement

SpringerLink
Log in

Antipsychotic utilization patterns among patients with schizophrenic disorder: a cross-national analysis in four countries

  • Pharmacoepidemiology and Prescription
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

The aim of the present study was to describe antipsychotic utilization patterns among patients with schizophrenic disorder in Italy, Spain, the UK, and the USA.

Methods

A retrospective cohort study was conducted. Patients aged 15 and over with schizophrenic disorder were identified in the Caserta claims database (Italy), the Valencia electronic medical record (EMR) database (Spain), in The Health Improvement Network EMR database (UK), and in databases of publicly and privately insured populations in the United States (US).

Results

The frequency of first-generation or second-generation antipsychotic use and of long-acting or other formulations was described. Persistence to antipsychotics was estimated. Overall, 1,403,240 patients with schizophrenic disorder having a total of 765,573 new antipsychotic treatment episodes were identified. The median follow-up time ranged from 0.8 (IQR 0.2–1.9) years in the US commercially-insured population to 1.2 (IQR 0.1–1.7) years in the Spanish population. Second-generation antipsychotics were more frequently used than first-generation antipsychotics in all countries (on average, from 64.4% in the UK to 87% in US): the use of this class increased over time in Italy, Spain, and US (Medicaid). The use of long-acting formulations was heterogeneous across countries, but generally much lower than other formulations. Persistence to antipsychotic treatment at 1 year was low in all countries, ranging from 40 in Spain to 30% in Italy.

Conclusions

Antipsychotic utilization was heterogeneous among persons with schizophrenic disorder. Nevertheless, low persistence was an issue in all the countries, as less than half of the patients continued their treatment beyond 1 year.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Abrams DJ, Rojas DC, Arciniegas DB (2008) Is schizoaffective disorder a distinct categorical diagnosis? A critical review of the literature. Neuropsychiatr Dis Treat 2008;4(6):1089–1109

  2. Gayer-Anderson C, Morgan C (2013) Social networks, support and early psychosis: a systematic review. Epidemiol Psychiatr Sci 22(2):131–146

    Article  CAS  PubMed  Google Scholar 

  3. Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM (2004) Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 161(3):473–479

    Article  PubMed  Google Scholar 

  4. Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J (1999) Prediction of homelessness within three months of discharge among inpatients with schizophrenia. Psychiatr Serv 50(5):667–673

    Article  CAS  PubMed  Google Scholar 

  5. Olfson M, Marcus SC, Wan GJ (2009) Treatment patterns for schizoaffective disorder and schizophrenia among Medicaid patients. Psychiatr Serv 60(2):210–216

    Article  PubMed  Google Scholar 

  6. Schennach R, Riedel M, Musil R, Möller HJ (2012) Treatment response in first-episode schizophrenia. Clin Psychopharmacol Neurosci 10(2):78–87

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Haddad PM, Brain C, Jan Scott J (2014) Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas 5:43–62

    Article  PubMed  PubMed Central  Google Scholar 

  8. De Araújo AN, de Sena EP, de Oliveira IR et al (2012) Antipsychotic agents: efficacy and safety in schizophrenia. Drug Healthc Patient Saf 4:173–180

    PubMed  PubMed Central  Google Scholar 

  9. Werner FM, Coveñas R (2014) Safety of antipsychotic drugs: focus on therapeutic and adverse effects. Expert Opin Drug Saf 13(8):1031–1042

    Article  CAS  PubMed  Google Scholar 

  10. Rodríguez-Bernal CL, Hurtado I, García-Sempere A et al (2017) Oral anticoagulants initiation in patients with atrial fibrillation: real-world data from a population-based cohort. Front Pharmacol 8:63

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. García-Sempere A, Hurtado I, Sanfélix-Genovés J et al (2017) Primary and secondary non-adherence to osteoporotic medications after hip fracture in Spain. The PREV2FO population-based retrospective cohort study. Sci Rep 7(1):11784

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Sultana J, Fontana A, Giorgianni F, Pasqua A, Cricelli C, Spina E, Gambassi G, Ivanovic J, Ferrajolo C, Molokhia M, Ballard C, Sharp S, Sturkenboom M, Trifirò G (2016) The effect of safety warnings on antipsychotic drug prescribing in elderly persons with dementia in the United Kingdom and Italy: a population-based study. CNS Drugs 30(11):1097–1109

    Article  CAS  PubMed  Google Scholar 

  13. Ingrasciotta Y, Giorgianni F, Marcianò I et al (2016) Comparative effectiveness of biosimilar, reference product and other erythropoiesis-stimulating agents (ESAs) still covered by patent in chronic kidney disease and Cancer patients: an Italian population-based study. PLoS One 11(5):e0155805

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Patorno E, Glynn RJ, Levin R et al (2017) Benzodiazepines and risk of all cause mortality in adults: cohort study. BMJ 358:j2941

    Article  PubMed  PubMed Central  Google Scholar 

  15. Patorno E, Huybrechts KF, Bateman BT, Cohen JM, Desai RJ, Mogun H, Cohen LS, Hernandez-Diaz S (2017) Lithium use in pregnancy and the risk of cardiac malformations. N Engl J Med 376(23):2245–2254

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Gaviria AM, Franco JG, Aguado V, Rico G, Labad J, de Pablo J, Vilella E (2015) A non-interventional naturalistic study of the prescription patterns of antipsychotics in patients with schizophrenia from the Spanish Province of Tarragona. PLoS One 10(10):e0139403

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Patel MX, Bishara D, Jayakumar S, Zalewska K, Shiers D, Crawford MJ, Cooper SJ (2014) Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales. Eur Neuropsychopharmacol 24(4):499–509

    Article  CAS  PubMed  Google Scholar 

  18. Lawson W, Johnston S, Karson C, Offord S, Docherty J, Eramo A, Kamat S, Blanchette CM, Carson W, Nasrallah HA (2015) Racial differences in antipsychotic use: claims database analysis of Medicaid-insured patients with schizophrenia. Ann Clin Psychiatry 27(4):242–252

    PubMed  Google Scholar 

  19. Trifirò G, Spina E, Brignoli O et al (2005) Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999-2002. Eur J Clin Pharmacol 61(1):47–53

    Article  PubMed  Google Scholar 

  20. Pesa JA, Muser E, Montejano LB, Smith DM, Meyers OI (2015) Costs and resource utilization among Medicaid patients with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics. Drugs Real World Outcomes 2(4):377–385

    Article  PubMed  PubMed Central  Google Scholar 

  21. Pilon D, Joshi K, Tandon N et al (2017) Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic. Patient Prefer Adherence 11:619–629

    Article  PubMed  PubMed Central  Google Scholar 

  22. Gaviria AM, Franco J, Rico G, Muntané G, Sáez C, Sánchez-Gistau V, de Pablo J, Vilella E (2017) Noninterventional, naturalistic, retrospective study to describe prescription patterns of long-acting injectable antipsychotics and the impact of introducing a new atypical antipsychotic in the Spanish Province of Tarragona catchment area. Prim Care Companion CNS Disord 19(2)

  23. Greene M, Yan T, Chang E, Hartry A, Touya M, Broder MS (2018) Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ 21(2):127–134

    Article  PubMed  Google Scholar 

  24. MacEwan JP, Forma FM, Shafrin J, Hatch A, Lakdawalla DN, Lindenmayer JP (2016) Patterns of adherence to oral atypical antipsychotics among patients diagnosed with schizophrenia. J Manag Care Spec Pharm 22(11):1349–1361

    PubMed  Google Scholar 

  25. Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, Lam A, Villalobos Vega JC, Cuéllar JA, de Castro FJ, Quintero CM, Martíin JF, Domínguez P, Ojeda JL, Cortés SS, Cala FI, Marín CG, Castro LM, Duaso MA, Albarracín JR, Vergara GN, Benítez AF, Cleries FM, Pérez-Brian JM, Aragón AB, Navarro JC, Biedma JA, de Pedro RB, González JF, López ME, Moreno HD, López JA, Rodríguez EO, de Hoyos CM, Sacristán MP, Martín MD, Ballesteros EM, Rodríguez PA, Menéndez LF, Rivas RS, del Pino Cuadrado P, Lauffer JC, Solano JJ, Martínez JM, Solano FG, Rodríguez PG, Rodríguez JA, Cano TR, Fortacin MD, Lobeiras JM, Sampedro JM, Bravo AP, Pellicer AF, López MD, Liste JF, Fernández MR, Losada AC, Mendez RV, Romero SA, Blanco JJ, Bonaselt IT, Mahia MC, del Valle E, Yañez PQ, Camarasa MG, Alonso JA, Mendez GF, Feliz FD, Lamela MA, Piñero MV, Alvarado PF, Gómez IL, Martín PF, Gómez JL, López AG, Jiménez AR, Nafs AE, Barquero NC, Ortiz RF, Noguera JL, Carrasco PR, Muñoz JM, Palma MM, Hortelano CM, Bonome LS, Sevilla JS, Juan JM, Ramos JM, Muñoz JL, Guisasola JE, Vazquez LS, Guerras FC, Nebot FJ, Fernández FJ, Nicolau AL, Subirats RC, Kidias MM, Navarro VF, García BF, del Rosal F, de Vicente Muñoz T, Ballester JA, Lieb PM, Martel AD, Bea ER, Joaquim IG, Enjuanes FB, Piñol MB, Carbonell EF, Muñoz RM, Giribets CA, Sans LA, Blanco AS, Felipe MA, Muñoz PG, Villanueva AP, Arroyo MB, Borri RC, Fallada SM, Merola MC, Rodon EP, Palmes JR, Martínez EP, Catala JM, Coca AS, Ferrandiz FP, Paya EF, Caballero GI, Bonet AF, Figueras JF, Pagador PM, Garibo MM, Camo VP, Carrillo CS, Valero CP, Rebollo FJ, García Campayo J, Sala Ayma JM, Roig MM, de Uña Mateos MA, Bertolin RG, García AM, Mazo FJ, Velasco JL, Pérez LS, Casado CJ, Barba JJ, Diaz MC, Rubio JP, Mandoli AS, Herrero AU, Martínez AR, Serrano PS, Rodríguez EN, Montesinos JS, Macia JF, Mateos Marcos AM, Soto JV, Dumont MV, Pagan JP, Martínez VB, Santiuste de Pablos M, Delgado CE, Quiles MD, López FJ, Navarro PP, Torres AM, Ingles FJ, Arias-Camison JM, Manzano JC, Peña RV, Guitarte GP, Fontecilla HB, Romero JB, Gil RS, Lozano JM, Adanez LD, Zarranz Herrera-Oria I, Jiménez JP, Vaz FC, García OS, Anton CC, Casula RR, Hernandez MC, Escabias FT, Torresano JR, Pérez-Villamil AH, Estevez L, Figuero MA, Muñoz de Morales A, Calvin JL, Criado MD, Rodríguez VM, Ambrosolio EB, Madera PM, Alfaro GP, Vidal MM, Valtuille AG, Ruiz O, Cabornero GL, Echevarria Martínez de Bujo M, Mallen MJ, Puigros JS, Martorell AL, Forteza AC, Arrebola ER, Rodríguez de la Torre M, Saiz CG, Bardolet I Casas C, Linde ER, de Arce Cordon R, Molina EM, Carazo FJ, Romero JJ, Cano DV, Dorado MS, Velazquez SC, Sánchez AJ, Leon SO, Sánchez KP, Benitez MH, Zugarramurai AI, Contreras MA, de la Varga González M, Marín PB, Robina FG, García MS, Pérez FJ, Bros PC, Gómez AC, de Dios Molina Martín J, Perera JL, Averbach MC, Perera JL, Palancares EG, Gallego de Dios MT, Rojo CF, Iglesias SS, Merino MI, Mestre NP, Urdaniz AP, Sánchez JM, Seco RG, Muñoz JF, Agut MM, Lozano ML, Herguedas FM, Pena AT, García JV, Martínez AV, Sanz Granado OS, Fernández MA, Canseco JM, López PA, Martín MA, Barrio JA, Ubago JG, Bennassar MR, Díez JM, Fleta JL, Fortes FP, López CA, Medina O, Alvarez DF, Roca JM, Valladolid GR, Tavera JA, García-Castrillon Sales JA, Llordes IB, Melgarejo CA, Cañas de la Paz F, Callol VV, García MB, García JB, Leal FJ, Corrales EC, Iglesias ES, Gómez MA, Serrano GG, Chillarón EG, Aguado FJ, Castillo JJ, González AG, Vázquez JG, Peralvarez MB, Diaz MR, Mesa MY, Artiles FJ, Chao MA, Mesa MY, del Rosario Santana P, Escudero MA, Berenguer MM, Llacer JM, Berna JA, Ortiz JB, Pardell LT, Hernández-Alvarez de Sotomayor C, Méndez MR, Garate RC, Múgica BD, González MC, Domingo JP, Navarro CS, Vera GS, Cuquerella MA, Monzo JL, Boada PC, Pérez MF, Parrado EC, Sánchez JJ, Fernández JC, e-STAR Spanish Study Group (2009) Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 24(5):287–296

    Article  CAS  PubMed  Google Scholar 

  26. National Institute for Health and Care Excellence (NICE). Clinical guideline [CG178]: psychosis and schizophrenia in adults: prevention and management. Published date: February 2014. Last updated: March 2014. Available from: https://www.nice.org.uk/guidance/CG178/chapter/1-Recommendations#choice-of-antipsychotic-medication. Accessed on 12/06/2017

  27. Higashi K, Medic G, Littlewood KJ, Diez T, Granström O, de Hert M (2013) Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol 3(4):200–218

    Article  PubMed  PubMed Central  Google Scholar 

  28. Jiang Y, Ni W (2015) Estimating the impact of adherence to and persistence with atypical antipsychotic therapy on health care costs and risk of hospitalization. Pharmacotherapy 35(9):813–822

    Article  PubMed  Google Scholar 

  29. Costa E, Giardini A, Savin M, Menditto E, Lehane E, Laosa O, Pecorelli S, Monaco A, Marengoni A (2015) Interventional tools to improve medication adherence: review of literature. Patient Prefer Adherence 9:1303–1314

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Via Consolare Valeria, 98125, Messina, Italy

    Janet Sultana, Francesco Giorgianni & Gianluca Trifirò

  2. Health Services Research Unit, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), Valencia, Spain

    Isabel Hurtado, Daniel Bejarano-Quisoboni & Gabriel Sanfélix-Gimeno

  3. Red de Investigación en Servicios de Salud en Enfermedades Crónicas Valencia, Valencia, Spain

    Isabel Hurtado & Gabriel Sanfélix-Gimeno

  4. Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Krista F. Huybrechts, Zhigang Lu & Elisabetta Patorno

  5. Caserta Local Health Unit, Caserta, Italy

    Daniele Ugo Tari

Authors
  1. Janet Sultana
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Isabel Hurtado
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel Bejarano-Quisoboni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Francesco Giorgianni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Krista F. Huybrechts
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhigang Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Elisabetta Patorno
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gabriel Sanfélix-Gimeno
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Daniele Ugo Tari
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Gianluca Trifirò
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gianluca Trifirò.

Ethics declarations

Disclosure of potential conflicts of interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(PDF 189 kb)

ESM 2

(PDF 185 kb)

ESM 3

(PDF 185 kb)

ESM 4

(PDF 188 kb)

ESM 5

(PDF 189 kb)

ESM 6

(PDF 186 kb)

ESM 7

(PDF 186 kb)

ESM 8

(PDF 186 kb)

ESM 9

(PDF 187 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sultana, J., Hurtado, I., Bejarano-Quisoboni, D. et al. Antipsychotic utilization patterns among patients with schizophrenic disorder: a cross-national analysis in four countries. Eur J Clin Pharmacol 75, 1005–1015 (2019). https://doi.org/10.1007/s00228-019-02654-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-019-02654-9

Keywords

Search

Navigation